Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Change in Receivables (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Change in Receivables data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Change in Receivables rose 340.72% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, down 4.94%, while the annual FY2025 figure was $1.6 million, 4.94% down from the prior year.
  • Change in Receivables reached $1.6 million in Q4 2025 per TLSI's latest filing, up from -$497000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.6 million in Q4 2025 and bottomed at -$736000.0 in Q4 2022.
  • Average Change in Receivables over 4 years is $353538.5, with a median of $366000.0 recorded in 2025.
  • Peak YoY movement for Change in Receivables: surged 1965.71% in 2024, then crashed 341.26% in 2025.
  • A 4-year view of Change in Receivables shows it stood at -$736000.0 in 2022, then skyrocketed by 168.21% to $502000.0 in 2023, then fell by 28.09% to $361000.0 in 2024, then surged by 340.72% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $1.6 million in Q4 2025, -$497000.0 in Q3 2025, and $174000.0 in Q2 2025.